Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Headache
Headache Posters (7:00 AM-5:00 PM)
125
Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has proven efficacy in the preventive treatment of migraine in adults. 
To assess the effect of fremanezumab treatment on the total burden of migraine in patients with episodic or chronic migraine (EM/CM).
This post hoc analysis used data from three phase 3 studies: HALO EM (patients with EM), HALO CM (patients with CM), and FOCUS (patients with EM or CM and inadequate response to 2-4 prior migraine preventive medication classes). In all 3 trials, patients were randomized 1:1:1 to receive quarterly fremanezumab, monthly fremanezumab, or matched placebo over 12 weeks. To assess the monthly total migraine burden, severity-weighted duration of migraine days (in hours) was calculated by multiplying hours of migraine recorded and pain severity (rated 0=none to 3=severe) for each migraine day and summing these composite measures over migraine days per month. 
The monthly total migraine burden (monthly average severity-weighted duration of migraine days) at baseline was similar in the quarterly fremanezumab, monthly fremanezumab, and placebo groups, respectively, in the HALO EM (115.2, 111.6, and 113.0 hours), HALO CM (234.3, 250.2, and 253.5 hours), and FOCUS (225.8, 238.1, and 242.1 hours) studies. Reductions from baseline in the monthly total migraine burden (in hours) over 12 weeks of double-blind treatment were greater with fremanezumab versus placebo in the HALO EM study (least-squares mean change from baseline: quarterly, −48.3; monthly, −56.4 vs placebo, −29.1; both P≤0.0001), HALO CM study (quarterly, −94.6; monthly, −100.6 vs placebo, −56.5; both P<0.0001), and FOCUS study (quarterly, −70.0; monthly, −75.1 vs placebo, −9.0; both P<0.0001).
Greater reductions in the monthly total migraine burden, including frequency, severity, and duration, were seen with quarterly and monthly fremanezumab versus placebo for patients with EM and CM, including those with difficult-to-treat migraine.
Authors/Disclosures
Christina Sun-Edelstein, MD (St Vincent's Hospital Melbourne)
PRESENTER
Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Sun-Edelstein has received publishing royalties from a publication relating to health care.
Joshua *use 125685 Cohen (Teva Pharmaceuticals Industries) Joshua Cohen has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Sanjay Gandhi, MD (Teva Pharmaceuticals) Dr. Gandhi has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Nahum Nesher (Tel Aviv Medical Center) Steve Barash has received personal compensation for serving as an employee of Teva. Steve Barash has received stock or an ownership interest from Teva.
Jan Lewis Brandes, MD (Nashville Neuroscience Group, P.C.) Dr. Brandes has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Brandes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Brandes has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Lilly. Dr. Brandes has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Amgen. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Brandes has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Lewis Thomason. Dr. Brandes has received research support from Amgen. Dr. Brandes has received research support from Teva. Dr. Brandes has received research support from Allergan. Dr. Brandes has received research support from Biohaven. Dr. Brandes has a non-compensated relationship as a Board Member with National Headache Foundation that is relevant to AAN interests or activities.